The Janus Henderson Anemoy AAA CLO Fund (JAAA) currently shows 78.6% utilization with $448.98 million in DeFi active TVL against $571.22 million in active AUM. LlamaRisk proposed increasing JAAA’s loan-to-value (LTV) limit on Aave Horizon from 81% to 87% and raising the liquidation threshold from 86% to 89%, which would allow higher borrowing capacity and increase maximum leverage from 5.26x to 7.69x. This change means positions would be liquidated after a 2.25% net asset value drop. The proposal is under review through the Risk Steward process and aims to enhance liquidity options for non-U.S. professional investors holding tokenized AAA-rated CLO tranches.
The Janus Henderson Anemoy AAA CLO Fund (JAAA) shows a 78.6% utilization rate with $448.98 million in active DeFi TVL as of October 20, 2026. For readers following major cryptocurrencies on Pluang, 32 out of 50 priced assets rose today. Notable movers include BAT with a 10.29% increase to Rp3.477, EOS up 8.13% to Rp12.649, and CRV down 4.43% to Rp6.644. This snapshot is as of Oct 20, 2026 07:21 WIB.
Anteris Technologies received regulatory approval from Germany's BfArM to start enrolling patients in its global PARADIGM trial for the DurAVR Transcatheter Heart Valve. This approval allows the company to recruit patients at leading German centers, ...
XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...
XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...
Nvidia announced a nearly $10 billion investment plan to support Europe's AI ecosystem, focusing on four German startups: Agile Robots, Avelios Medical, Mirelo, and Reflex Aerospace. This move aligns with Germany's goal to lead in industrial AI, with...
Recce Pharmaceuticals has reached a key milestone in its Phase 3 trial for treating diabetic foot infections with its RECCE® 327 Gel (R327G). An independent Data Monitoring Committee will review unblinded data from 75 patients, following encouraging ...
